ILLUMINATE Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Objective== | ==Objective== | ||
Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor. | |||
==Dates== | ==Dates== | ||
===Start Date=== | ===Start Date=== | ||
August 23, 2004 | |||
===End Date=== | ===End Date=== | ||
Premature Termination on December 2, 2006. Data collection continued till July 15, 2007. | |||
==Methods== | ==Methods== | ||
Revision as of 11:56, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ILLUMINATE Trial On the Web |
|
American Roentgen Ray Society Images of ILLUMINATE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.
Dates
Start Date
August 23, 2004
End Date
Premature Termination on December 2, 2006. Data collection continued till July 15, 2007.